Although hyperlipidemia is common in COPD, its relationship to comorbidities, risk factors and lung function in COPD has not been studied in detail. Using the baseline data of the COSYCONET cohort we addressed this question. Data from 1746 COPD patients (GOLD stage 1–4; mean age 64.6 y, mean FEV1%pred 57%) were evaluated, focusing on the comorbidities hyperlipidemia, diabetes and cardiovascular complex (CVC; including arterial hypertension, cardiac failure, ischemic heart disease). Risk factors comprised age, gender, BMI, and packyears of smoking. The results of linear and logistic regression analyses were implemented into a path analysis model describing the multiple relationships between parameters. Hyperlipidemia (prevalence 42.9%) was associated with lower intrathoracic gas volume (ITGV) and higher forced expiratory volume in 1 second (FEV1) when adjusting for its multiple relationships to risk factors and other comorbidities. These findings were robust in various statistical analyses. The associations between comorbidities and risk factors were in accordance with previous findings, thereby underlining the validity of our data. In conclusion, hyperlipidemia was associated with less hyperinflation and airway obstruction in patients with COPD. This surprising result might be due to different COPD phenotypes in these patients or related to effects of medication.
Citation: Kahnert K, Lucke T, Huber RM, Behr J, Biertz F, Vogt A, et al. (2017) Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS ONE 12(5): e0177501. https://doi.org/10.1371/journal.pone.0177501
Editor: Stelios Loukides, National and Kapodistrian University of Athens, GREECE
Received: March 30, 2017; Accepted: April 30, 2017; Published: May 15, 2017
Copyright: © 2017 Kahnert et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by BMBF Competence Network Asthma and COPD (ASCONET) and performed in collaboration with the German Center for Lung Research (DZL). The project is funded by the German Federal Ministry of Education and Research (BMBF) with grant number 01 GI 0881; and is funded by unrestricted grants from AstraZeneca GmbH, Bayer Schering Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Chiesi GmbH, GlaxoSmithKline, Grifols Deutschland GmbH, MSD Sharp & Dohme GmbH, Mundipharma GmbH, Novartis Deutschland GmbH, Pfizer Pharma GmbH, Takeda Pharma Vertrieb GmbH & Co. KG for patient investigations and laboratory measurements.
Competing interests: Dr. Bals reports grants from Grifols, personal fees from GSK, AstraZeneca, Boehringer Ingelheim, outside the submitted work; Dr. Ficker reports grants from Cosyconet study supported by Bundesministerium fuer Bildung und Forschung BMBF, during the conduct of the study; personal fees from Boehringer, grants, personal fees and non-financial support from CSL-Behring, personal fees from GSK, personal fees from AstraZeneca, personal fees from Roche, personal fees and non-financial support from Novartis, from null, outside the submitted work; Dr. Fähndrich reports grants from CSL Behring, grants from Grifols, grants from AstraZeneca, outside the submitted work; Dr. Holle reports grants from German Federal Ministry of Education and Research (grant number 01GI0882), during the conduct of the study; Dr. Karrasch reports grants from German Federal Ministry of Education and Research (BMBF) with grant number 01GI0882, during the conduct of the study; Dr. Wacker reports grants from German Federal Ministry of Education and Research (grant number 01GI0882), during the conduct of the study;Dr. Vogelmeier reports personal fees from Almirall, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants and personal fees from Grifols, personal fees from Mundipharma, personal fees from Novartis, personal fees from Takeda, personal fees from Cipla, personal fees from Berlin Chemie/Menarini, outside the submitted work; Dr. Jörres reports grants from German Federal Ministry of Education and Research (grant number 01GI0882), during the conduct of the study, as well as Grants from MundiPharma, GSK and Lufthansa that are not related to the present work. The rest of the authors have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Hyperlipidemia is a major risk factor for cardiovascular diseases which are common comorbidities in patients with chronic obstructive pulmonary disease (COPD) , but there are only limited studies on its role in COPD itself [2, 3]. Although most comorbidities are associated with increased mortality, retrospective analyses revealed a decreased incidence of pneumonia and reduced mortality in COPD patients with hyperlipidemia [4, 5]. Thus the role of hyperlipidemia remains unclear and its relationship to other comorbidities, risk factors and pulmonary function has to be studied in more detail.
In subjects with metabolic syndrome and hyperlipidemia but no obvious lung disease a restrictive spirometric lung function pattern was observed [6–8], but this has not been verified e.g. by bodyplethysmography. The relation of hyperlipidemia to lung function in COPD is unclear but of interest owing to physiological findings. Lipoproteins can influence blood rheology, including plasma viscosity, aggregation and deformation of erythrocytes [9, 10], and in vitro they led to accumulation of erythrocytes in the pulmonary capillary bed . Thus it has been hypothesized that a higher capillary red cell volume would lead to an increase in the diffusing capacity for carbon monoxide (TLCO). At least in lung-healthy subjects, however, there was no difference in TLCO between subjects with and without hyperlipidemia [11–13].Whether this also applies to patients with COPD is not known.
Based on these considerations the aim of our study was to analyze the relationship of hyperlipidemia to lung function, risk factors and comorbidities linked to hyperlipidemia in patients with COPD. For this purpose we used data from the German COSYCONET (“COPD and SYstemic consequences-COmorbidities NETwork”) COPD cohort .
Material and methods
The analysis was based on the baseline data set (visit 1) of COSYCONET which is a multi-center study focusing on the role of comorbidities in COPD . Only patients of COPD severity GOLD 1–4  with complete data on forced expiratory volume in 1 second (FEV1), intrathoracic gas volume (ITGV) and transfer coefficient for carbon monoxide (KCO), as well as on age, gender, packyears of smoking, body-mass index (BMI) and the comorbidities hyperlipidemia, diabetes, and cardiovascular complex (see below) were included. This resulted in a study population of n = 1746 out of 2741 patients recruited into COSYCONET . The study had been approved by the ethical committees of all study centers and all patients gave their written informed consent.
Ethics approval and consent to participate
All assessments were approved by the central (Marburg (Ethikkommission FB Medizin Marburg) and local (Bad Reichenhall (Ethikkommission bayerische Landesärztekammer); Berlin (Ethikkommission Ärztekammer Berlin); Bochum (Ethikkommission Medizinische Fakultät der RUB); Borstel (Ethikkommission Universität Lübeck); Coswig (Ethikkommission TU Dresden); Donaustauf (Ethikkommission Universitätsklinikum Regensburg); Essen (Ethikkommission Medizinische Fakultät Duisburg-Essen); Gießen (Ethikkommission Fachbereich Medizin); Greifswald (Ethikkommission Universitätsmedizin Greifswald); Großhansdorf (Ethikkommission Ärztekammer Schleswig-Holstein); Hamburg (Ethikkommission Ärztekammer Hamburg); MHH Hannover / Coppenbrügge (MHH Ethikkommission); Heidelberg Thorax/Uniklinik (Ethikkommission Universität Heidelberg); Homburg (Ethikkommission Saarbrücken); Immenhausen (Ethikkommission Landesärztekammer Hessen); Kiel (Ethikkommission Christian-Albrechts-Universität zu Kiel); Leipzig (Ethikkommission Universität Leipzig); Löwenstein (Ethikkommission Landesärztekammer Baden-Württemberg); Mainz (Ethikkommission Landesärztekammer Rheinland-Pfalz); München LMU/Gauting (Ethikkommission Klinikum Universität München); Nürnberg (Ethikkommission Friedrich-Alexander-Universität Erlangen Nürnberg); Rostock (Ethikkommission Universität Rostock); Berchtesgadener Land (Ethikkommission Land Salzburg); Schmallenberg (Ethikkommission Ärztekammer Westfalen-Lippe); Solingen (Ethikkommission Universität Witten-Herdecke); Ulm (Ethikkommission Universität Ulm); Würzburg(Ethikkommission Universität Würzburg)) ethical committees and written informed consent was obtained from all patients. The study was conducted from September 2011 to December 2013 within the COSYCONET framework (ClinicalTrials.gov, Identifier: NCT01245933) . The approval by the central ethics committee (University of Marburg) and the ethics committees of all other studies centers (including University of Munich) comprises the statement that the study can be conducted. This includes not only the collection of data but also the permission that the analyses of the data outlined in the study protocol, as well as study questions developed on the basis of accumulated experience and the collected data, can be performed. An additional approval is only required if additional data are collected which were not part of the initial approval or if patient-sensitive analyses are to be performed, such as genetic analyses of collected samples without previous approval by the patient. In their written informed consent the patients also agreed to the scientific evaluation of the collected data. The specific aim of the present study, which comprised the analysis of three comorbidities and selected lung function parameters, is therefore implicitly included in the approval by the ethics committees. Naturally, in such a large cohort study including multiple parameters not all specific study questions can be explicitly formulated from the beginning. The question of the present study was contained in the bullet point “zu untersuchen, ob die Kombination funktioneller Indizes, systemischer Marker und klinischer Diagnosen es erlaubt, bislang unbekannte Phänotypen der COPD zu definieren, die möglicherweise einer unterschiedlichen Verlaufskontrolle und Therapie bedürfen”(translated: to study whether the combination of functional indices, systemic markers and clinical diagnoses allows the definition of novel phenotypes of COPD which possibly require a different monitoring over time and therapy).
Protocol and methods have been described previously . To facilitate the comparison with previous cohorts we described the characteristics of our study population by a panel of parameters as well as the conventional categorizations (1–4 and ABCD) according to GOLD . Moreover we used the conventional percentages of mean predicted values based on the fact that the data on the deviations allowing for a lower limit of predicted was heterogeneous among the predictions equations for the different parameters used. For the present analysis comorbidities were assumed if either patients reported a doctor-based diagnosis, irrespective of medication, or in the absence of a report, if disease-specific medication was identified; the details of the procedure and the medication are given in a previous publication . These definitions were named „extended definitions“. Since in cardiovascular diseases medication often is not specific for a single diagnosis but for two or three, we combined the three comorbidities “arterial hypertension”, “cardiac failure” and “ischemic heart disease” into „cardiovascular complex” . The analysis was restricted to three comorbidities known to be closely linked to each other based on clinical observations. Moreover in these comorbidities disease-specific medication could be used to higher degree than in a variety of other comorbidities; the complete list of comorbidities is given in our previous publication .
Lung function comprised spirometry, body plethysmography and carbon monoxide (CO) diffusing capacity . In addition to FEV1, ITGV and KCO, for the description of the population the forced vital capacity (FVC), the ratio FEV1/FVC and transfer factor for CO (TLCO) were chosen, each as percent of predicted. For the path analysis FEV1, ITGV and KCO were taken as representatives of the domains obstruction, hyperinflation and gas exchange limitation. Predicted values of FEV1, FEV1/FVC, FVC were taken from GLI , of ITGV from EGKS , and of TLCO and KCO from van der Lee et al. . As major risk factors we included BMI, age, gender and packyears.
Data are presented as mean values and standard deviations (SD). Comparisons between the two groups with and without hyperlipidemia were performed with the unpaired t-test irrespective of potential small deviations from normality (Kolmogorov-Smirnov-test) which commonly have no major impact on the test result. However, to be on the safe side and to check whether these deviations affected the result we additionally employed the Mann-Whitney-U-test and explicitly give the results for both types of tests. Categorical variables were compared between groups using cross-tabulation and the chi-square-test statistics.
Next the association between variables was evaluated by standard multivariate linear and binary logistic regression analyses comprising one dependent and multiple independent variables. These types of analyses are however limited to describe complex relationships in networks that can be represented by only two types of variables: dependent and independent. A potential relationship between dependent variables as well as the possibility that the same variable is both dependent and independent can be modeled by path analysis . All analyses were performed using SPSS Statistics 23 (IBM Corp., Armonk, NY, USA) and AMOS (IBM Corp., Armonk, NY, USA). Statistical significance was assumed for p<0.05.
Table 1 shows the patients’ characteristics (n = 1746) stratified for hyperlipidemia. In all parameters except for FVC%pred, FEV1/FVC and TLC%pred there were significant differences between the two groups, in both parametric and non-parametric testing. For comparison the values for the total COSYCONET study population (GOLD 1–4, n = 2238) are given in S1 Table; patients with and without hyperlipidemia again significantly differed in all parameters except FEV1/FVC and TLC%pred. For selected lung function parameters the differences between hyperlipidemia groups remained significant after adjustment for risk factors and are illustrated in Fig 1.
The figure shows the differences between patients with and without hyperlipidemia for three selected lung function parameters representing airway obstruction, lung volume and alveolar gas exchange. These differences are based on multivariate regression analyses adjusting for age, gender, BMI and packyears, as major confounders some of which were different between groups. The circles represent mean values and the vertical bars 95% confidence intervals, showing that even after adjustment there were significant (p<0.05) differences in FEV1 and ITGV.
Fig 2 shows the prevalence of hyperlipidemia in patients with and without diabetes or cardiovascular complex. Both were significantly (p<0.001 each) associated with hyperlipidemia. Overall these results showed that (a) our observations were in accordance with other cohorts and that (b) it would be reasonable to implement the relationships between comorbidities, and not only their relation to risk factors or lung function, into a statistical model.
Results of path analysis models
We first performed standard multivariate linear and logistic regression analyses (see Tables A-C in S1 Text). Based on their results we constructed a sequence of path analysis models which allowed the description of more complex relationships, particularly between dependent variables. To build a final model in a systematic way, two preliminary models were evaluated (see S1 and S2 Figs). In this model the variables were arranged into three „layers“: on top the risk factors (BMI, age, gender, packyears), as intermediates the comorbidities (diabetes, hyperlipidemia, cardiovascular complex), and at the bottom lung function (ITGV%pred, FEV1%pred, KCO%pred).
Final model comprising risk factors, comorbidities and lung function.
The final model (Fig 3) was constructed as a composite of the two preliminary models (S1 and S2 Figs). Based on the regression results (Table C in S1 Text) we additionally introduced a number of relationships between comorbidities and lung function but kept only those which turned out to be statistically significant, i.e. that between hyperlipidemia and ITGV and that between cardiovascular complex and FEV1. Parameter values and significance levels of the final model are shown in Table 2. The model fitted the data with a chi-squared of 18.79 at 21 degrees of freedom (p = 0.60; see above) and was also well-fitting according to the bootstrap procedure using 2000 samples and the Bollen-Stine method (chi-squared 21.54, p = 0.61).
Final path analysis model comprising three layers: risk factors, comorbidities and lung function parameters. The structure only contains relationships which turned out to be statistically significant (p<0.05 each). Error terms of dependent variables have been omitted for the sake of clarity. Correlations between the independent variables are indicated by arched arrows.
In the present analysis we investigated the relationship between risk factors, comorbidities and lung function in a large cohort of patients with COPD. The comorbidities comprised a combination of cardiovascular diseases and diabetes, as well as hyperlipidemia [2, 3]. Its prevalence was 42.9% according to self-reported doctors’ diagnoses and disease-specific medication. Based on linear and logistic regression results an integrative path analysis model was built that illustrated the place of hyperlipidemia in the network of risk factors, other comorbidities and lung function. Hyperlipidemia was dependent on age, BMI, diabetes and cardiovascular diseases. Even after adjustment for confounders it was associated with lower ITGV and higher FEV1, beyond the direct and indirect links from BMI and age. This apparently protective effect might be related to the phenotype of COPD as well as beneficial effects of medication targeted at hyperlipidemia. In our analyses we required complete data sets and therefore had to exclude a number of patients. However comparison of the descriptive Table 1 and S1 Table does not indicate a selection bias introduced by this.
To understand the relationship between the different entities we first performed multivariate regression analyses comprising the risk factors age, packyears, BMI and gender, the three comorbidities and a variety of lung function parameters. For path analysis we focused on single representatives of obstruction (FEV1%pred), hyperinflation (ITGV%pred) and gas exchange (KCO%pred). Among the comorbidities a combined entity “cardiovascular complex” was defined comprising arterial hypertension, cardiac failure and ischemic heart disease. The comorbidities depended on age, BMI and partially on gender (Table A in S1 Text), while lung function depended on BMI, age and gender, diffusing capacity additionally on packyears (Table B in S1 Text). Diabetes was related to lung volume and diffusing capacity, cardiovascular complex to obstruction and lung volume, and hyperlipidemia to all three lung function parameters (Table C in S1 Text).
Thus hyperlipidemia was linked to risk factors as well as lung function. It was associated with relatively better FEV1, while diabetes and cardiovascular complex were linked to relatively lower FEV1. The observation regarding hyperlipidemia and FEV1 appeared to be in contrast to findings in obese lung-healthy subjects  but in COPD the situation might be more complicated due to the presence of risk factors influencing both lung function and comorbidities. To analyse the complex network of direct and indirect effects we used the statistical procedure of path analysis.
Path analysis is a well-founded statistical procedure widely used in empirical social sciences and econometrics ; it has also been used in medical studies to evaluate complex associations [22, 23]. Essentially it is an extension of multivariate regression allowing for hierarchical relationships as well as bypassing these hierarchies and thus the quantification of both direct and indirect effects all of which can be visualized graphically; indirect effects are those mediated through other variables (see S1 Text). The possibility to introduce relationships between dependent variables accounts for known or suspected links between them, in addition to the “downward” relationships quantified by conventional regression. We first analysed two preliminary models which comprised risk factors and either comorbidities (S1 Fig) or lung function (S2 Fig). These models showed that (a) the assumed additional relationships were statistically valid and (b) that no further significant relationships could be demonstrated. Irrespective of this it has to be kept in mind that path analysis is a hypothesis-driven procedure and that in general there may be statistically equivalent models. The choice between them has to be based on physiological and clinical knowledge. On the other hand the procedure is capable of excluding models that do not adequately describe the data .
The final model (Fig 3) was constructed as overlay of the preliminary models. Additionally we introduced relationships between comorbidities and lung function taking into account the results of the respective regression analysis (Table C in S1 Text). Only the relationships between hyperlipidemia, FEV1%pred and ITGV%pred remained as significant and were kept in the model. It seems remarkable that these direct links from hyperlipidemia were still relevant when multiple confounders were taken into account but this was in accordance with comparisons adjusting for risk factors (Fig 1). The link from hyperlipidemia to ITGV acted in parallel to the direct effect of BMI and had the same sign, i.e. hyperlipidemia was associated with less hyperinflation. This reduction of ITGV might reflect an additional mechanical influence in obese subjects that is not adequately described by BMI, such as a different distribution of body mass. To check this possibility we repeated the analysis with waist circumference as predictor instead of BMI. The overall model fit was still acceptable, and the links between hyperlipidemia and ITGV%pred as well as FEV1%pred remained significant. Therefore we considered BMI as adequate in the model.
Among the comorbidities of COPD known to be linked to hyperlipidemia, diabetes and cardiovascular diseases are the most prevalent ones . We therefore restricted the analysis to these two conditions. One of the advantages was that these comorbidities could also be evaluated via analysis of disease-specific medication in addition to patients’ report . This however required that the three diseases arterial hypertension, cardiac failure and ischemic heart disease were combined into to a single entity termed “cardiovascular complex”, since many medications are specific for a combination of these diseases but not for a single one. Comparing to reported diagnoses, the prevalence for diabetes increased through the consideration of specific medication from 12.6 to 12.9%, for the cardiovascular complex from 60.0 to 64.7%, and for hyperlipidemia from 37.9 to 42.9%. Probably the estimates including the information from medication are more reliable than those based on reports only. When using the latter, the overall fit of the model was reduced but still significant; importantly, the links between hyperlipidemia, ITGV and FEV1 remained significant. This indicates that the extended definitions of comorbidities (a) improved the results and (b) did not introduce artefacts compared to the reported diagnoses.
As risk factors we considered age and gender, as well as packyears and BMI, which were either independent of the individual behaviour, or linked to lifestyle. All of them are known to be correlated with comorbidities and lung function, and indeed their association with cardiovascular diseases was consistent with previous findings . The same was true for the associations between BMI and hyperlipidemia  or diabetes , or between diabetes and cardiovascular diseases , or between diabetes, cardiovascular diseases and hyperlipidemia . This suggests that the COSYCONET data set did not deviate from other data sets in a significant way, irrespective of the diagnosis of COPD. In particular this refers to the link between hyperlipidemia and lung volume which turned to be robust in various statistical analyses. The comorbidities were part of the final model in order to include as much as possible of the known confounders and thereby to identify both direct and indirect associations of hyperlipidemia via their standardized effects (see legend to Table 2). For example, hyperlipidemia was directly linked to age (Table 2; standardized effect 0.045; see also Fig 2) but also indirectly linked to age via diabetes as well as cardiovascular complex which corresponded to an overall indirect effect of 0.039. Thus direct and indirect effects were of similar magnitude. This type of quantification is possible only with path analysis through multiplication of the respective standardized coefficients.
The findings regarding lung volume fit into the hypothesis that COPD patients with higher BMI and/or hyperlipidemia more often show a COPD phenotype of obstructive bronchitis rather than emphysema. We did not have such phenotype information, e.g. based on CT scans, and the pattern of lung function alterations did not uniquely allow the differentiation. The observed inverse association between ITGV and FEV1 (Table 2) is known but not specific for emphysema , and the relationship between BMI and relatively higher FEV1 is consistent with less emphysema in patients of higher weight . The direct link from packyears to lower KCO possibly reflected the degree of emphysema, thereby abolishing a potential effect of dyslipidemia (Fig 1), and the association of higher ITGV with lower KCO (Table 2) their known volume-based relationship. As TLCO is directly proportional to lung volume we preferred the use of KCO, although KCO also does not fully normalize for volume. Moreover the model fit with KCO was superior to that with TLCO.
The positive association between hyperlipidemia and FEV1 (Table 2) might be surprising at the first view but is not necessarily in conflict with findings that lung-healthy subjects with hyperlipidemia/metabolic syndrome showed a reduced FEV1, since we studied patients with COPD, i.e. inflammatory lung disease. Remarkably, patients with COPD and hyperlipidemia appear to have a better outcome in pneumonia-related exacerbations and mortality [4, 5]. It may also be noteworthy that several studies described an anti-inflammatory action of simvastatin , an improved FEV1 in patients undergoing this therapy  a protective effect against the development of emphysema , in accordance with the, on average, better FEV1 and KCO in our patients (Table 1). Whether hyperlipidemia-related inflammation favours a specific phenotype of COPD is not known; for diabetes CT data indicate a predominant non-emphysematous type of COPD . Although the differences of lung function parameters between both groups were small, they might become relevant in case of exacerbations.
The diagnosis of hyperlipidemia used in our analyses was based on patients’ reports and medication, while the effectiveness of their lipid-lowering therapy was illustrated by the comparison of patients with and without the diagnosis of hyperlipidemia (Table 1 and S1 Table). This was the reason why we could not use lipids for the definition of hyperlipidemia and did not include them into the path analysis. Overall 23.8% of patients received hyperlipidemia-specific medication , the others either non-specific medication and/or dietetics recommendations. When ITGV%pred was evaluated with BMI, age, gender and packyears as confounders, it turned out to be still significantly reduced for both patients with specific and non-specific medication. These observations show that the major difference in patients with the diagnosis of hyperlipidemia compared to those without was the presence of medication and not an increase in lipid levels. It is therefore tempting to attribute our findings to effects of medication.
One of the limitations of our study was that we could characterize the population by conventional lipid parameters but hardly include these in the analyses since they apparently were affected by therapy. A similar situation occurred for cardiovascular diseases. We therefore preferred not to use biomarkers in this analysis. The identification of comorbidities was based on patients’ reports only but we tried to alleviate this limitation as much as possible by using the extended, medication-based definitions. Moreover we did not have detailed information on the phenotype of COPD, e.g. from CT scans. The strength of the study was the large data set, the possibility to evaluate three comorbidities by analysis of medication, and the use of path analysis beyond conventional multivariate regression. The statistical evaluation of the model depended on assumptions on data distribution which were not met with our data, but we used asymptotically distribution-free estimation in a sufficiently large data set  and the fit was confirmed by other estimation procedures. Furthermore we incorporated into the final model as much as possible of the already known associations thereby aiming to describe the role of hyperlipidemia in COPD in the whole context of other alterations.
Using the large baseline data set of the German COPD cohort COSYCONET we evaluated the relationship between risk factors, hyperlipidemia, diabetes, a combination of cardiovascular diseases and lung function. Hyperlipidemia was associated with lower ITGV and higher FEV1 even if its direct and indirect links to diabetes and cardiovascular disease, or age, gender and BMI were taken into account, and there was no hint towards an impairment of lung function associated with hyperlipidemia, similar to that previously found for diabetes. The result was statistically robust within a path analysis model and multivariate regression analyses suggesting that COPD patients with hyperlipidemia showed less lung hyperinflation and airway obstruction than those without hyperlipidemia. Whether this reflected differences in COPD phenotype or was related to other factors including medication remains to be clarified.
S1 Fig. Premliminary path analysis model 1.
Preliminary path analysis model comprising two layers, on the top risk factors and as intermediate layer comorbidities. All of the relationships shown were statistically significant (p<0.05 each). Error terms of dependent variables have been omitted for the sake of clarity. There were no significant correlations between the independent variables.
S2 Fig. Preliminary path analysis model 2.
Preliminary path analysis model comprising two layers, on the top risk factors and as bottom layer lung function parameters. All of the relationships shown were statistically significant (p<0.05 each). Error terms of dependent variables have been omitted for the sake of clarity. There were no significant correlations between the independent variables.
S1 Table. Baseline characteristics of the subgroups with and without hyperlipidemia (n = 2238, total cohort GOLD 1–4).
The table shows mean values and standard deviations or absolute numbers. Lung function parameters are given in terms of %predicted, except for alveolar volume, VA, which is given in liters. Column 4 shows the results of comparisons between the hyperlipidemia group (extended definition) and the complementary group of non-hyperlipidemia patients. The comparisons between groups were performed by unpaired t-tests, either for equal or unequal variances depending on the data, or by chi-square-tests in the case of categorical variables. The results of t-tests were checked by the Mann-Whitney-U-test to accommodate for deviations from normality; the results of both approaches were qualitatively equivalent. Significant (p<0.05) differences are marked with (*).
Lead author (Head of the Steering Committee): Prof. Dr. Claus Vogelmeier
Study site/ prinicpal investigator
Philipps-Universität Marburg/ Prof. Dr. Claus Vogelmeier
Medizinische Hochschule Hannover/ Prof. Dr. Tobias Welte
Klinik für Pneumologie
Medizinische Klinik/Campus Innenstadt/ Prof. Dr. Huber
Wissenschaftliches Institut Bethanien e.V./ Prof. Dr. Winfried J. Randerath
Institut für Pneumologie an der Universität Witten/Herdecke
Aufderhöhe Straße 169–175
Thoraxklinik-Heidelberg gGmbH/ Prof. Dr. Felix Herth
Pneumologie und Beatmungsmedizin
Universität des Saarlandes/ Prof. Dr. Dr. Robert Bals
FR. 2.7 /Innere Medizin V
Abt. Pneumologie, Geb. 91
Kirrberger Str. 100
Universitätsmedizin Greifswald/ Prof. Dr. Ralf Ewert
Klinik und Poliklinik für Innere Medizin B
Kliniken Südostbayern AG/ Dr. Christian Geltner
Kreisklinik Bad Reichenhall
Pneumologie, Lungenzentrum SüdOst
83435 Bad Reichenhall
Dr. Margret Jandl
Berufsgenossenschaftliches Universitätsklinikum/ Prof. Dr. Andrea Koch/ Dr. Juliane Kronsbein
Klinik Donaustauf/ Prof. Dr. Michael Pfeifer
Zentrum für Pneumologie
Fachkrankenhaus Coswig GmbH/ Prof. Dr. Gerd Höffken
Zentrum für Pneumologie, Thorax- und Gefäßchirurgie
Neucoswiger Str. 21
Universitätsklinikum Heidelberg/ Prof. Dr. Hugo A. Katus
Innere Medizin III
Im Nauenheimer Feld 672
Fachklinik für Lungenerkrankungen Immenhausen/ Prof. Dr. Stefan Andreas
Pneumologische Lehrklinik der Universität Göttingen
Philippstiftung e. V.
Universitätsklinikum Schleswig-Holstein/ Prof. Dr. Burkhardt Bewig
Klinik für Innere Medizin I
Arnold-Heller-Str. 3, Haus 6
Forschungszentrum Borstel/ Prof. Dr. Peter Zabel
Leibnitz-Zentrum für Medizin und Biowissenschaften
Pneumologisches Forschungsinstitut an der Lungenclinic Grosshansdorf GmbH/ PD Dr. Henrik Watz/ PD Dr. Anne-Marie Kirsten
Justus-Liebig-Universtität Gießen/ Prof. Dr. Werner Seeger
Zentrum für Innere Medizin
Medizinische Klinik und Poliklinik II
Asklepios Klinik München-Gauting/ Prof. Dr. Jürgen Behr
Hemholtz Zentrum München
Klinikum Nürnberg Nord/ Prof. Dr. Joachim Ficker
Universitätsklinikum Ulm/ Dr. Cornelia Kropf-Sanchen
Studienzentrale Innere Medizin II/Pneumologie
Ev. Lungenklinik Berlin/ Prof. Dr. Christian Grohé
Lindenberger Weg 27
Universität Leipzig/ Prof. Dr. Hubert Wirtz
Missionsärztliche Klinik/ Prof. Dr. Berthold H. Jany
Gemeinnützige Gesellschaft mbH
Schön Klinik/ Prof. Dr. Klaus Kenn
83471 Schönau am Königsee
Krankenhaus Lindenbrunn, Coppenbrügge/ Dr. Manfred Gogol
Klinik Löwenstein gGmbH/ Prof. Dr. Ulrich Wagner
Universitätsmedizin der Johannes-Gutenberg-Universität Mainz/ Prof. Dr. Roland Buhl
Gebäude 406, II OG
III. Medizinische Klinik
Universitätsklinikum Rostock/ Prof. Dr. J. Christian Virchow
Zentrum für Innere Medizin
Abt. für Pneumologie
Ruhrlandklinik gGmbH Essen/ Prof. Dr. H. Teschler
Tüschener Weg 40
- Conceptualization: KK RAJ TL RMH JB FB AV HW SF RB CV PA RH.
- Data curation: KK RAJ TL SS FB.
- Formal analysis: KK RAJ PA.
- Investigation: KK RAJ HW RB CV.
- Methodology: KK RAJ PA.
- Project administration: KK RAJ.
- Supervision: RAJ CV.
- Validation: FB RH MW.
- Visualization: KK RAJ.
- Writing – original draft: KK RAJ.
- Writing – review & editing: TL RMH JB AV HW PA SF RH SK SS MW JHF KGP CV FB.
- 1. Akhabue E, Thiboutot J, Cheng JW, Vittorio TJ, Christodoulidis G, Grady KM, et al. New and emerging risk factors for coronary heart disease. Am J Med Sci. 2014;347(2):151–8. Epub 2013/05/07. pmid:23644407
- 2. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):549–55. Epub 2008/05/06. pmid:18453370
- 3. Negewo NA, McDonald VM, Gibson PG. Comorbidity in chronic obstructive pulmonary disease. Respir Investig. 2015;53(6):249–58. Epub 2015/11/02. pmid:26521102
- 4. Chan MC, Lin CH, Kou YR. Hyperlipidemia in COPD is associated with decreased incidence of pneumonia and mortality: a nationwide health insurance data-based retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2016;11:1053–9. Epub 2016/06/09. pmid:27274227
- 5. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–61. Epub 2012/05/09. pmid:22561964
- 6. Ford ES, Cunningham TJ, Mercado CI. Lung function and metabolic syndrome: Findings of National Health and Nutrition Examination Survey 2007–2010. J Diabetes. 2014;6(6):603–13. Epub 2015/12/18. pmid:26677470
- 7. Chen WL, Wang CC, Wu LW, Kao TW, Chan JY, Chen YJ, et al. Relationship between lung function and metabolic syndrome. PLoS One. 2014;9(10):e108989. Epub 2014/10/10. pmid:25299452
- 8. Yoshimura C, Oga T, Chin K, Takegami M, Takahashi K, Sumi K, et al. Relationships of decreased lung function with metabolic syndrome and obstructive sleep apnea in Japanese males. Intern Med. 2012;51(17):2291–7. Epub 2012/09/15. pmid:22975537
- 9. Aviram M, Viener A, Brook JG. Reduced plasma high-density lipoprotein and increased platelet activity in arterial versus venous blood. Postgrad Med J. 1987;63(736):91–4. Epub 1987/02/01. pmid:3671249
- 10. Lowe GD, McArdle BM, Stromberg P, Lorimer AR, Forbes CD, Prentice CR. Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinaemia. Lancet. 1982;1(8270):472–5. Epub 1982/02/27. pmid:6121140
- 11. Pintaric I, Eterovic D, Tocilj J, Reiner Z, Lusic I. Effect of simvastatin on micropulmonary red cell mass in patients with hyperlipoproteinemia. Atherosclerosis. 2001;154(2):493–6. Epub 2001/02/13. pmid:11166784
- 12. Newball HH, Friedewald WT, Roberts B, Levy RI, Lenfant CJ. Effect of elevated triglycerides on the diffusing capacity of man. Am Rev Respir Dis. 1975;112(1):83–8. Epub 1975/07/01. pmid:1147387
- 13. Partridge MR, Hughes JM, Thompson GR. Effect of hyperlipidaemia on pulmonary diffusing capacity for carbon monoxide. Thorax. 1979;34(2):265–8. Epub 1979/04/01. pmid:483198
- 14. Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, et al. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27–37. Epub 2016/04/26. pmid:27109808
- 15. Soriano JB, Lamprecht B, Ramirez AS, Martinez-Camblor P, Kaiser B, Alfageme I, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med. 2015;3(6):443–50. Epub 2015/05/23. pmid:25995071
- 16. Lucke T, Herrera R, Wacker M, Holle R, Biertz F, Nowak D, et al. Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies–A Novel Stepwise Approach by Evaluation of Medication. PLoS One. 2016;11(10):e0163408. pmid:27792735
- 17. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43. Epub 2012/06/30. pmid:22743675
- 18. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40. Epub 1993/03/01. pmid:8499054
- 19. van der Lee I, Zanen P, Stigter N, van den Bosch JM, Lammers JW. Diffusing capacity for nitric oxide: reference values and dependence on alveolar volume. Respir Med. 2007;101(7):1579–84. Epub 2007/01/19. pmid:17229562
- 20. Hoyle RH, editor. Handbook of Structural Equation Modeling 2015.
- 21. Leone N, Courbon D, Thomas F, Bean K, Jego B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179(6):509–16. Epub 2009/01/13. pmid:19136371
- 22. Tawakol A, Ishai A, Takx RA, Figueroa AL, Ali A, Kaiser Y, et al. Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. Lancet. 2017. Epub 2017/01/16.
- 23. Silove D, Rees S, Tay AK, da Costa ZM, Savio ES, Soares C, et al. Pathways to perinatal depressive symptoms after mass conflict in Timor-Leste: a modelling analysis using cross-sectional data. Lancet Psychiatry. 2015;2(2):161–7. Epub 2015/09/12. pmid:26359752
- 24. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999;99(9):1165–72. Epub 1999/03/09. pmid:10069784
- 25. Humayun A, Shah AS, Alam S, Hussein H. Relationship of body mass index and dyslipidemia in different age groups of male and female population of Peshawar. J Ayub Med Coll Abbottabad. 2009;21(2):141–4. Epub 2009/04/01. pmid:20524492
- 26. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61(5):737–47. Epub 2007/05/12. pmid:17493087
- 27. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134–46. Epub 1999/09/08. pmid:10477542
- 28. Santus P, Radovanovic D, Henchi S, Di Marco F, Centanni S, D'Angelo E, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir Physiol Neurobiol. 2014;197:36–45. pmid:24726342
- 29. Guerra S, Sherrill DL, Bobadilla A, Martinez FD, Barbee RA. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest. 2002;122(4):1256–63. pmid:12377850
- 30. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64–70. Epub 2001/07/04. pmid:11434828
- 31. Bando M, Miyazawa T, Shinohara H, Owada T, Terakado M, Sugiyama Y. An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease. Respirology. 2012;17(3):493–8. Epub 2011/12/07. pmid:22142478
- 32. Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005;172(8):987–93. Epub 2005/07/09. pmid:16002570
- 33. Hersh CP, Make BJ, Lynch DA, Barr RG, Bowler RP, Calverley PM, et al. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med. 2014;14:164. Epub 2014/10/25. pmid:25341556